Article - 19/05/2008 "Fast-track" route to a PhD degree The Chemical Biology graduate school at Constance University was officially opened on 7th May 2008. It was created as part of Germanys excellence initiative and has been training doctoral students since the beginning of April 2008.https://www.gesundheitsindustrie-bw.de/en/article/press-release/fast-track-route-to-a-phd-degree
Press release - 07/12/2021 New approach developed to predict response of immunotherapies in lung cancer At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of Medical Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-developed-predict-response-immunotherapies-lung-cancer
Press release - 14/03/2012 How a natural antibiotic found in sweat affects microorganisms The skin creates a barrier between the body and its environment. Natural antibiotics that can kill potential pathogens such as bacteria or fungi represent an additional level of protection by the immune system. Dermcidin one such antibiotic produced in human sweat glands is active against a number of microorganisms on the skin. A team of scientists from the University Hospital Tübingen and the Max Planck Institute for Developmental Biology were…https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-a-natural-antibiotic-found-in-sweat-affects-microorganisms
Press release - 03/03/2020 CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force Daniel Menichella, CEO of biopharmaceutical company CureVac, was today invited to the White House to discuss strategies and opportunities for the rapid development and production of a coronavirus vaccine with U.S. President Donald Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and high-ranking representatives of pharmaceutical and biotech companies working on the outbreak’s response. https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-CEO-Daniel-Menichella-Discusses-Coronavirus-Vaccine-Development-with-U-S-President-Donald-Trump-and-Members-of-Coronavir
Press release - 15/07/2021 Mechanism for differentiation of specific immune cell types discovered Under certain conditions, our immune system can efficiently fight off infectious diseases and cancer. T cells, especially the gamma delta T cell type, play an important role in this. The issue is that this cell type is extremely infrequent in the human body. Researchers at the University Hospital Tübingen, the University of Heidelberg and the European Molecular Biology Laboratory (EMBL) have now succeeded in finding the cause for the formation of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/mechanism-differentiation-specific-immune-cell-types-discovered
Press release - 01/02/2021 Targeting a rapid market breakthrough for new vaccine production method In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product. https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method
Press release - 07/08/2009 Hirschsprung’s disease: research into the biological and clinical principles of stem cell therapy Hirschsprung’s disease is a congenital disease of the intestinal nervous system, which can lead to life-threatening bowel disorders. A new research project, which is being coordinated by the Centre for Regenerative Biology and Medicine (ZRM) in Tübingen, is paving the way for a novel cell therapy. The project is being carried out in co-operation with the NMI in Reutlingen and is being funded by a 1.1-million-euro BMBF-grant. https://www.gesundheitsindustrie-bw.de/en/article/press-release/hirschsprung-s-disease-research-into-the-biological-and-clinical-principles-of-stem-cell-therapy
Press release - 30/03/2009 Stem Cells: Deathly Awakening by Interferon Interferon-alpha, a messenger substance of the immune system, awakens dormant hematopoietic stem cells in the bone marrow to become active, thus making them vulnerable for the effect of many drugs. This finding was published in Nature by researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) jointly with colleagues from Lausanne. The researchers suppose that this might also be a way to stimulate tumor stem…https://www.gesundheitsindustrie-bw.de/en/article/press-release/stem-cells-deathly-awakening-by-interferon
SolidCAR-T project - 15/03/2022 Modular ‘mini-factories’ for decentralised production of CAR T cells Novel CAR T-cell therapies have proved to be promising therapeutic options for the treatment of acute leukaemias and lymphomas. Researchers from the Fraunhofer IPA in Stuttgart, the University Hospital Tübingen and the NMI in Reutlingen have joined forces in the SolidCAR-T project that aims to generate CAR T cells to combat solid tumours and produce these cells directly on site in the clinic using automated 'mini-factories'.https://www.gesundheitsindustrie-bw.de/en/article/news/modular-mini-factories-decentralised-production-car-t-cells
Vaccine development - 02/11/2015 A new vaccine could prevent influenza epidemics Influenza pandemics are dangerous and can claim many lives. Children and the elderly in particular run a high risk of developing influenza-related complications, because their immune system is often weakened by the virus. In Germany, annual vaccination against seasonal influenza has therefore been recommended for these target groups for quite a few years now. However, producing vaccines is costly and time-consuming. Researchers at the University…https://www.gesundheitsindustrie-bw.de/en/article/news/a-new-vaccine-could-prevent-influenza-epidemics
Article - 20/09/2016 CRISPR-Cas has more surprises in store Since 2012, a DFG-funded research group called FOR1680 has been studying CRISPR-Cas, an immune system that unicellular bacteria and arachaea use to protect themselves against attacks from viruses and plasmids. Prof. Dr. Anita Marchfelder, a molecular biologist at Ulm University and coordinator of the FOR1680 research group, and many other researchers were surprised to find that prokaryotes incorporate the genetic material of enemies as a kind of…https://www.gesundheitsindustrie-bw.de/en/article/news/crispr-cas-has-more-surprises-in-store
Article - 18/02/2013 AIDS researchers from Ulm to shed light on the success of the HIV-1 M group Frank Kirchhoff AIDS researcher at the University of Ulm has come up with a plausible explanation for the pandemic spread of the human immunodeficiency virus 1 HIV-1 M group and its ability to adapt to the human immune system. In a recent study with colleagues from Germany and abroad Kirchhoff used molecular biology methods to investigate the group and compare it with the relatively rare HIV-1 N group. Kirchhoff hopes that the molecular…https://www.gesundheitsindustrie-bw.de/en/article/news/aids-researchers-from-ulm-to-shed-light-on-the-success-of-the-hiv-1-m-group
Article - 16/01/2012 Alexander Titz: molecular design to combat antibiotic-resistant bacteria Pseudomonas aeruginosa has become an important cause of infection, and is often picked up in hospitals, especially by patients with weakened immune systems. It can cause respiratory and urinary tract infections, as well as lead to infections on implants and wounds. P. aeruginosa lives in a gel-like matrix, a so-called biofilm that is highly resistant to antibiotics, making it very difficult to eradicate. Dr. Alexander Titz and his team at the…https://www.gesundheitsindustrie-bw.de/en/article/news/alexander-titz-molecular-design-to-combat-antibiotic-resistant-bacteria
Press release - 08/10/2012 Affimed raises € 15.5 million in a Series D financing round Affimed Therapeutics AG the therapeutic TandAb antibody company announced the successful closing of a Series D financing round of 15.5 million on 8 October 2012. The proceeds from this transaction will be used to fund the clinical development of Affimeds therapeutic pipeline that consists of two TandAb products AFM11 and AFM13. Both candidates have unique properties as shown in preclinical studies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-raises-15-5-million-in-a-series-d-financing-round
Press release - 13/11/2012 immatics’ renal cancer vaccine IMA901 completes phase 3 patient recruitment immatics biotechnologies GmbH announced that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma RCC. The first interim overall survival results are expected during the first half of 2014.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-renal-cancer-vaccine-ima901-completes-phase-3-patient-recruitment
Article - 12/11/2012 Autoimmune diseases – when the body sheds its skin Most people believe that snakes and insects are the only animals able to shed their skin. However autoimmune diseases of the largest human organ i.e. the skin can have a similar effect by creating blisters scars peeling and wet wounds. Dr. Cassian Sitaru from the University of Freiburg Medical Centre specifically focuses on blistering autoimmune dermatoses. Using disease models in Petri dishes and laboratory mice Sitaru and his team hope to find…https://www.gesundheitsindustrie-bw.de/en/article/news/autoimmune-diseases-when-the-body-sheds-its-skin
Article - 19/09/2019 Magnetised algae as microrobots for medical and environmental purposes Algae, for most of us, is something that lives in water courses that we occasionally find unpleasant. However, that is to do them a wrong. These extremely versatile and frugal organisms might in future prove to be extremely important. Scientists at the University of Stuttgart are investigating how algae can be used as microrobots in biomedicine and environmental remediation.https://www.gesundheitsindustrie-bw.de/en/article/news/magnetisierte-algen-als-mikroroboter-fuer-medizin-und-umwelt
Dossier - 10/03/2014 Cancer therapy and cancer diagnostics Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones, are difficult to treat. Therapies targeting immune cells or cancer stem cells could potentially improve the current situation. The early detection and classification of tumours is crucial for the successful treatment of the disease, and molecular…https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-therapy-and-cancer-diagnostics
Press release - 15/10/2020 Common Vulnerabilities of Coronaviruses International study in which Freiburg scientists are participating maps molecular targets for possible therapy for MERS, SARS-CoV1, and SARS-CoV2.https://www.gesundheitsindustrie-bw.de/en/article/press-release/common-vulnerabilities-coronaviruses
Press release - 12/03/2009 New strategy for the investigation of haematopoietic stem cells With the newly developed mouse model irradiation is no longer required. While the mutation in the growth factor receptor Kit KitWWv weakens the recipients stem cell compartment and makes room for the incoming donor cells the other two mutations are known to prevent rejection of donor haematopoietic stem cells by the recipients immune system. Thus these mice appear to accept all blood stem cells regardless of the mouse strain origin of the…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-strategy-for-the-investigation-of-haematopoietic-stem-cells
Article - 22/02/2016 Generating malaria parasite gene deletion mutants The fight against malaria is one of the targets of goal 3 of the Sustainable Development Goals (SDGs) (ensuring healthy lives and promote well-being for all at all ages). The research carried out by Prof. Dr. Frischknecht and Mirko Singer from the Centre for Infectious Diseases at Heidelberg University Hospital is one of several steps towards eradicating malaria. https://www.gesundheitsindustrie-bw.de/en/article/news/generating-malaria-parasite-gene-deletion-mutants
Article - 20/11/2011 Can probiotic lactic acid bacteria protect the intestines against pathogens? Nutrition scientists from the Max Rubner-Institut MRI in Karlsruhe are investigating how human pathogens and probiotic bacterial strains interact with each other in the human gastrointestinal tract. Are probiotic bacteria in yoghurt or in pickled vegetables for example able to reduce the health risk posed by pathogenic bacteria?https://www.gesundheitsindustrie-bw.de/en/article/news/can-probiotic-lactic-acid-bacteria-protect-the-intestines-against-pathogens
Article - 14/02/2011 A molecule that enables local virus defence Dr. Markus Mordstein has spent the last four years as a doctoral student at the University of Freiburg investigating the previously relatively unknown interferon lambda. He has been able to show that this molecule has similar protective functions to type I interferons and he has also found that it is far more selective in terms of the site where it exerts its effect.https://www.gesundheitsindustrie-bw.de/en/article/news/a-molecule-that-enables-local-virus-defence
Article - 04/02/2020 Medicine from the blue blood of marine mollusks A “living pharmacy” crawls on the ocean floor off the coastline that stretches from Southern California to Mexico: biosyn Arzneimittel GmbH, a pharmaceutical company based in the city of Fellbach in southern Germany, produces a drug to treat bladder cancer, using the haemolymph, a vertebrate fluid equivalent to blood, of Megathura crenulata, commonly known as a giant keyhole limpet.https://www.gesundheitsindustrie-bw.de/en/article/news/medicine-from-blue-blood-marine-snails
Press release - 23/05/2011 Interactive exhibition on health opened on Mainau Island Can neurons grow together again? Is the immune system able to combat cancer? Can a chip help blind people regain their sight? As part of the “Science in Dialogue” (Wissenschaft im Dialog) initiative, the “Lindau Nobel Laureate Meetings” foundation has organised an exhibition on health-related topics that will be open to visitors until 4th September 2011. BIOPRO Baden-Württemberg is in pavilion 11 presenting three exciting research topics from…https://www.gesundheitsindustrie-bw.de/en/article/press-release/interactive-exhibition-on-health-opened-on-mainau-island